Form 4: Madrigal Pharmaceuticals SVP and CFO, Mardi Dier, Sells Shares Under 10b5-1 Plan

Mardi Dier, SVP and CFO of Madrigal Pharmaceuticals, sold 258 shares of common stock at a price of $323.04 per share on March 10, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 10, 2025, Mardi Dier, the SVP and CFO of Madrigal Pharmaceuticals, sold 258 shares of the company's common stock.
• The sale was executed at a price of $323.04 per share.
• Following the transaction, Dier directly owns 10,440 shares of Madrigal Pharmaceuticals.
• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 13, 2024.

Sentiment

Score: 5

Explanation: The document reports a routine stock sale by an executive under a pre-arranged plan, which is neither particularly positive nor negative. The sentiment is neutral.

Industry Context

Sales by company insiders are a common occurrence and are often scrutinized by investors as they can provide insights into management's perspective on the company's valuation and future prospects. However, sales under a pre-arranged 10b5-1 trading plan are less likely to be indicative of the insider's current sentiment, as the plan was established in advance.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, potentially causing a slight decrease in stock price due to increased selling pressure, although the effect is likely to be minimal given the relatively small number of shares sold.

Key Dates